Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, NTNU, Norwegian University of Science and Technology, Trondheim, Norway.
Department of Gynecology, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway.
In Vivo. 2021 May-Jun;35(3):1595-1603. doi: 10.21873/invivo.12416.
Time-to-treatment is defined as a quality indicator for cancer care but is not well documented. We investigated whether meeting Norwegian timeframes of 35/42 days from referral until start of chemotherapy or surgery/radiotherapy for lung cancer was associated with survival.
The medical records of 439 lung cancer patients at a regional cancer center were reviewed and categorized according to treatment: (i) surgery; ii) radical radiotherapy; iii) stereotactic radiotherapy; iv) palliative treatment, no cancer symptoms; v) palliative treatment with severe cancer symptoms).
Proportions receiving timely treatment varied significantly at 39%, 48%, 10%, 44% and 89%, respectively (p<0.001). Overall, those starting treatment on time had the shortest median overall survival (10.6 vs. 22.6 months; p<0.001). This was also the case for palliative (5.3 vs. 11.4 months) (p<0.001) but not for curative treatment (not reached vs. 38.3 months) (p=0.038).
Timely treatment is not necessarily associated with improved survival.
治疗时间是癌症护理的质量指标，但尚未得到充分记录。我们研究了是否满足挪威从转诊到开始化疗或手术/放疗的 35/42 天时间框架与肺癌患者的生存情况有关。
对一家地区癌症中心的 439 名肺癌患者的病历进行了回顾，并根据治疗方式进行了分类：（i）手术；（ii）根治性放疗；（iii）立体定向放疗；（iv）姑息治疗，无癌症症状；（v）姑息治疗，有严重癌症症状）。
及时接受治疗的比例分别为 39%、48%、10%、44%和 89%，差异具有统计学意义（p<0.001）。总体而言，按时开始治疗的患者的中位总生存期最短（10.6 个月 vs. 22.6 个月；p<0.001）。这在姑息治疗（5.3 个月 vs. 11.4 个月）（p<0.001）和根治性治疗（未达到 vs. 38.3 个月）（p=0.038）中均如此。
及时治疗不一定与生存改善相关。
